SCHEMBL16010271

SCHEMBL16010271

CCCCCc1ccc2ncc(-c3cc4ccccc4s3)n2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.52
PIK3R1 P27986 1/20 0.52
FYN P06241 11/20 0.39
MKNK1 Q9BUB5 3/20 0.38
EIF4E P06730 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
TLR7 Q9NYK1 1/20 0.36
GRK5 P34947 1/20 0.35
DYRK3 O43781 1/20 0.35
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
CDK5 Q00535 1/20 0.35
DYRK1A Q13627 1/20 0.35
CDK5R1 Q15078 1/20 0.35
DYRK2 Q92630 1/20 0.35
DYRK1B Q9Y463 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16010248 0.83 FYN (0.45) PIK3CDPIK3R1FYN
SCHEMBL16010352 0.82 PIK3CD (0.67) PIK3CDPIK3R1FYNMKNK1CCNT1
SCHEMBL16023579 0.78 PIK3CD (0.55) PIK3CDPIK3R1FYNMKNK1EIF4E
SCHEMBL16009176 0.77 MKNK1 (0.50) PIK3CDPIK3R1MKNK1EIF4EMKNK2
SCHEMBL13234229 0.77 MKNK1 (0.55) PIK3CDPIK3R1FYNMKNK1EIF4E
SCHEMBL16554668 0.76 FYN (0.43) FYNGRK5
SCHEMBL3874890 0.74 PIK3CD (0.47) PIK3CDPIK3R1MKNK1
SCHEMBL2949024 0.73 PIK3CD (0.69) PIK3CDPIK3R1FYNMKNK1
SCHEMBL16010044 0.73 PIK3CD (0.56) PIK3CDPIK3R1FYNDYRK3CCNT1
SCHEMBL16008745 0.73 PIK3CD (0.56) PIK3CDPIK3R1FYNDYRK3CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. 2016-08-11 US disclosed
US-9370515-B2 Mixed lineage kinase inhibitors and method of treatments Califia Bio, Inc. (US) 2016-06-21 US disclosed
US-20140256733-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. (US) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS MAP3K2, MAP3K1, MAP3K20 PIK3CD 316/4885PIK3R1 436/4885FYN 521/4885
US-20140256733-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS MAP3K2, MAP3K1, MAP3K20 PIK3CD 316/4885PIK3R1 436/4885FYN 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.